

Ghayas C Issa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4473671/publications.pdf>

Version: 2024-02-01

47
papers

1,598
citations

331538

21
h-index

315616

38
g-index

48
all docs

48
docs citations

48
times ranked

1532
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2022, 12, 10.	2.8	48
2	Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancers</i> , 2022, 14, 150.	1.7	30
3	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2161-2170.	0.6	12
4	Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 751-758.	0.9	3
5	Hypomethylating agent and venetoclax with FLT3 inhibitor "triple" therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	2.8	33
6	Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	2.0	31
7	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	0.8	41
8	Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	4
9	The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 691-700.	3.3	37
10	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	2.0	59
11	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	2.6	50
12	Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer. <i>Acta Haematologica</i> , 2021, 144, 585-590.	0.7	3
13	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 25.	2.8	85
14	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	2.5	56
15	Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. <i>Blood Cancer Journal</i> , 2021, 11, 107.	2.8	73
16	Therapeutic implications of menin inhibition in acute leukemias. <i>Leukemia</i> , 2021, 35, 2482-2495.	3.3	76
17	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. <i>Blood Cancer Journal</i> , 2021, 11, 162.	2.8	32
18	Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> (<i>MLL</i>) rearrangement: the MD Anderson experience. <i>Blood Advances</i> , 2021, 5, 5415-5419.	2.5	24

#	ARTICLE	IF	CITATIONS
19	Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. <i>Blood Advances</i> , 2021, 5, 4569-4574.	2.5	15
20	Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution. <i>Leukemia Research</i> , 2021, 111, 106685.	0.4	2
21	Calibration-free NGS quantitation of mutations below 0.01% VAF. <i>Nature Communications</i> , 2021, 12, 6123.	5.8	13
22	CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. <i>Cancers</i> , 2021, 13, 5354.	1.7	3
23	Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. <i>Haematologica</i> , 2021, 106, 0-0.	1.7	6
24	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e724-e736.	2.2	201
25	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	2.2	43
26	Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. <i>Blood Cancer Journal</i> , 2020, 10, 47.	2.8	17
27	Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 48.	2.8	22
28	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. <i>Blood Cancer Journal</i> , 2020, 10, 61.	2.8	20
29	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. <i>Leukemia</i> , 2020, 34, 2914-2924.	3.3	7
30	Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. <i>Genes</i> , 2020, 11, 649.	1.0	29
31	Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. <i>Blood</i> , 2020, 136, 53-55.	0.6	8
32	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 645-645.	0.6	9
33	Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7039-7039.	0.8	0
34	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	0.8	156
35	A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7041-7041.	0.8	12
36	Poor outcomes associated with +der(22)t(9;22) and ~9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. <i>American Journal of Hematology</i> , 2017, 92, 238-243.	2.0	41

#	ARTICLE	IF	CITATIONS
37	Clonal chromosomal abnormalities appearing in Philadelphia chromosomeâ€“negative metaphases during CML treatment. <i>Blood</i> , 2017, 130, 2084-2091.	0.6	65
38	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467.	2.0	49
39	Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7033-7033.	0.8	3
40	Distinct patterns of somatic mutation clearance and association with clinical outcome in patients with AML.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7005-7005.	0.8	0
41	Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: Updated results of a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7037-7037.	0.8	0
42	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. <i>Cancer</i> , 2016, 122, 3812-3820.	2.0	17
43	Hyperâ€“CVAD plus ponatinib versus hyperâ€“CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2016, 122, 3650-3656.	2.0	156
44	Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. <i>Blood</i> , 2016, 128, 597-597.	0.6	0
45	Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1577-1577.	0.6	2
46	Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS. <i>Blood</i> , 2015, 126, 1663-1663.	0.6	5
47	Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD. <i>Blood</i> , 2015, 126, 4874-4874.	0.6	0